Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"
Manager TitleAgeSince
Chief Executive Officer - 21/03/2024
Director of Finance/CFO - 30/05/2024
Chief Tech/Sci/R&D Officer - 31/12/2014
Director TitleAgeSince
Director/Board Member - 31/12/2020
Director/Board Member - 21/03/2024
Director/Board Member - 30/05/2024
Change 5-day change 1-year change 3-year change Capi.($)
+5.43%-10.33% - - 2.99M
+2.91%-3.42%+2.89%-28.37% 15.28B
+2.09%-2.68%+33.17%+58.63% 1.59B
-0.13%+2.04%-29.57%+28.06% 1.11B
+2.43%-4.11%-56.09%-84.98% 814M
+2.60%+9.13%-14.28%-47.75% 700M
+4.71%+9.57%-36.49%-53.17% 609M
-0.95%+3.63%+32.96%-53.32% 443M
-0.16%-0.63%-54.51%-60.50% 382M
-2.53%-3.82%-25.47%-24.05% 340M
Average +1.61%-0.91%-16.38%-29.49% 2.36B
Weighted average by Cap. +2.50%-5.77%-1.33%-23.45%
Logo NEOS AB
NeoDynamics AB (publ) is a Sweden-based company engaged in the medical industry. The Company focuses on developing and commercializing products for breast cancer screening, imaging, and breast cancer treatments. The Company’s product NeoNavia, enables a pulse biopsy system for ultrasound guided tissue sampling. It consists of a base unit, a handheld driver and three different types of biopsy needles. Each needle type is driven by the pulse technology providing a more controlled needle insertion and precise placement of the needle in the tumour whilst enabling tissue samples from both breasts and lymph nodes. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is evaluated for breast cancer diagnosis at clinics in United Kingdom, Germany, and Sweden.
Employees
13
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!